Open-label study of an investigational product (IP), QLS-101, with 28-day every morning (QAM) dosing to both eyes (OU) in adolescents with SWS who have clinical evidence of glaucoma and/or ocular hypertension (OHT) related to SWS elevated EVP in at least one eye.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
2
ophthalmic solution in a single use dropper vial
Duke Eye Center
Durham, North Carolina, United States
Ocular safety
Incidence of ocular treatment emergent adverse events (TEAEs)
Time frame: Over 28 days
Systemic safety
Incidence of systemic TEAEs
Time frame: Over 28 days
Ocular hypotensive effectiveness
Mean change in intraocular pressure (IOP) (mmHg and % change) from baseline following 28 days dosing with QLS-101
Time frame: 28 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.